Phenindione - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for phenindione and what is the scope of freedom to operate?
Phenindione
is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for phenindione
US Patents: | 0 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 4 |
Patent Applications: | 5,221 |
Formulation / Manufacturing: | see details |
DailyMed Link: | phenindione at DailyMed |
Recent Clinical Trials for phenindione
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
NHS Lothian | Phase 3 |
University of Edinburgh | Phase 3 |
Chiltern International Inc. | Phase 3 |
Medical Subject Heading (MeSH) Categories for phenindione
Anatomical Therapeutic Chemical (ATC) Classes for phenindione
US Patents and Regulatory Information for phenindione
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | HEDULIN | phenindione | TABLET;ORAL | 008767-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |